SLNO: Soleno Therapeutics, Inc. - Summary | Jitta

Soleno Therapeutics, Inc.

NASDAQ:SLNO

Price
$53.01
Loss Chance
59.1%
0.72JITTA SCORE
66.76%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (20)
Recent Business Performance (69)
Financial Strength (67)
Return to Shareholders (20)
Competitive Advantage (31)
Jitta Signs
Recent Business PerformanceEarning Growth Last Year
Cash Conversion CycleLess than 30 days
New Share IssuedMore than 50% in 5 years
Key Stats
Jitta Score
Jitta Line
0.72
66.76%
2.21
145.02%
3.06
207.06%
Biotechnology
5.68
38.90%
5.68
38.90%
4.58
56.61%
COMPANY DESCRIPTION
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.